REDWOOD CITY, Calif., May 16, 2011 /PRNewswire/ — Arstasis is
pleased to announce the U.S. launch of its latest commercial
product – the AXERA™ Access Device. The AXERA Device
enhances insertability into the femoral artery and overall
procedural usage while continuing to deliver the clinical benefits
of the implant-free Arstaotomy Procedure.
Since 1959, physicians have been using the Modified Seldinger
Technique for femoral artery access. At the end of every such
case, patients are left with a substantial hole in the femoral
artery which can command significant effort and cath lab resources
to close. The AXERA™ Access Device is a breakthrough
femoral artery access tool that quickly creates a longer and
shallower angle arteriotomy, the Arstaotomy, resulting in
significant tissue-upon-tissue overlap through the artery. Upon
sheath removal at the end of the procedure, arterial pressure is
decreased across this longer Arstaotomy channel intended to
provide an excellent environment for clot formation and rapid
femoral artery hemostasis.
The AXERA Device’s Arstaotomy Procedure requires only minimal
manual compression to provide secure closure with no foreign body
implants – eliminating the risk of infections and thromboembolic
events related to a vascular implant. The Arstaotomy Procedure
promotes rapid hemostasis resulting in excellent patient comfort
with decreased bed rest and quicker ambulation.
“The AXERA Access Device delivers a truly unique way to gain
access into the femoral artery for diagnostic and cath-possible
procedures,” commented Dale Wortham, MD from the University of
Tennessee Medical Center, Knoxville. “Unlike vascular closure
implants, the AXERA Device delivers rapid arterial hemostasis but
does not deposit any foreign material into the patient. Our
results have been excellent with patients generally sitting up in
15 minutes and ambulating in 1 hour. It really has imp
‘/>”/>
